Core Insights - NeurAxis, Inc. has announced significant new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, from a major national health insurer, expanding its coverage to approximately 100 million lives across multiple states [1][3] Company Overview - NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4] - The company's proprietary technology, IB-Stim, is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia (FD) in patients aged 8 years and older [2][4] Product Details - IB-Stim is a non-invasive device that stimulates cranial nerve bundles in the ear to regulate pain signaling between the gut and the brain, addressing a significant unmet medical need in pediatric patients [2] - Currently, there are no FDA-approved drug therapies for pediatric patients with abdominal pain related to functional dyspepsia, making IB-Stim a unique solution in this market [2] Market Position and Future Outlook - The CEO of NeurAxis expressed optimism about securing additional coverage from large national insurers, highlighting the growing recognition of IB-Stim as an evidence-based therapy for pediatric gastrointestinal disorders [3] - With a Category I CPT code effective January 1, 2026, and incorporation into leading national society clinical practice guidelines, NeurAxis is positioned for significant revenue growth and margin expansion [3]
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives